Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
14.00    -0.50 (-3.45%)
Bid:
13.50
Ask:
14.50
Spread: 1.00 (7.407%)
Market Cap: £11.55m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Alusid raises £1.34m to scale up manufacturing

18 Sep 2018 13:56

RNS Number : 1499B
Frontier IP Group plc
18 September 2018
 

RNS / RNS

AIM: FIPP

18 September 2018

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Alusid raises £1.34 million to scale up manufacturing of innovative, sustainable building materials

 

 

Frontier IP, which specialises in commercialising university intellectual property, today announces that portfolio company, Alusid Limited (the "Company" or "Alusid"), has raised £1.34 million through a private funding round to support the design, planning and location of a new factory to transform its production capacity.

 

The fundraising has been supported by new and existing investors, including Frontier IP. The Group has converted a £348,000 loan into new equity in Alusid.

 

The fundraising values the Company at £4.86 million, meaning Frontier IP's 35.6 per cent stake is worth £1.73 million, up from the previous valuation of £700,000 for the 39 per cent held pre-fundraising. The funding round remains open for further investment up to a total of £1.75 million until 31 December 2018.

 

University of Central Lancashire spin-out Alusid uses a patented process to manufacture sustainable, high-quality building materials by recycling industrial waste ceramics and glass, which would otherwise go to landfill. Products are sold under the brand name SilicaStone.

 

Currently, the company makes table tops, tiles and other surfaces through a batch process using three kilns at its plant in Preston, Lancashire.

 

The proceeds of the fundraising will be invested in developing a new factory based on a continuous flow process, where products are fired by being fed onto a conveyer belt system, called a roller hearth tunnel kiln, in a steady stream.

 

The move follows the successful testing of a pilot production line with world-leading Italian ceramic -equipment company, Sacmi Group, which will also help to design the new factory. The Alusid process means the factory will be much more energy efficient than those used for making conventional tiles.

 

The plant is expected to start production in 2020. Once it is in operation, Alusid's capacity will rise from 4,000m2 a year to 30,000m2 a month, based on a single line producing tiles. Currently, it is estimated the cost of building a factory is about £10 million. Options being explored to finance the build include an initial public offering.

 

Alusid is attracting strong interest, and currently has more than 100 projects in its pipeline. SilicaStone buyers include Amazon, Four Seasons Hotels, Nando's and Wells Fargo bank, which is using the material in its prestigious new London HQ. The Company won this year's Jonathan Hindle Prize for outstanding design in 2D materials, awarded by The Furniture Makers' Company.

 

The Company is also actively exploring opportunities for international expansion, either through licensing or establishing joint ventures. Initial interest has been expressed by organisations in the United States, China and Portugal.

 

Allenby Capital Limited acted as broker to Alusid in connection with the funding round.

 

Alusid co-founder and chief operating officer Dr Alasdair Bremner said: "The building industry is increasingly looking for innovative sustainable products such as SilicaStone. This successful fund-raising will enable Alusid to move to the next stage in development where we can really capitalise on the economies of scale coupled with lower energy and material costs." 

 

Frontier IP chief executive Neil Crabb said: "We're delighted with the success of the Alusid funding round and the belief shown by investors in the potential of the Company. With consumers increasingly focused on sustainability and the impact of waste on the environment, we are confident that Alusid has a very bright future."

 

 

 

 

 

 

ENQUIRIES

 

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications and Investor Relations

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Cenkos Securities plc (Nominated Adviser and Joint Broker)

T: 0131 220 6939

Neil McDonald / Beth McKiernan

 

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Lucy Williams

 

Kreab (Financial PR)

T: 020 7074 1800

Robert Speed / Matthew Jervois

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of material equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOESFFFEAFASEIU
Date   Source Headline
30th Jun 20265:00 pmRNSTotal Voting Rights
26th Jun 202610:03 amRNSHolding(s) in Company
25th Jun 20262:44 pmRNSHolding(s) in Company
25th Jun 20267:00 amRNSHolding(s) in Company
24th Jun 20267:00 amRNS-RPortfolio news: Investment in Fieldwork Robotics
23rd Jun 20267:00 amRNSPosting of Circular and Notice of General Meeting
19th Jun 20267:00 amRNSResult of Retail Offer
17th Jun 20267:00 amRNSResult of Placing and Subscription
16th Jun 20265:20 pmRNSRetail Offer
16th Jun 20264:58 pmRNSProposed Placing and Subscription
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes
24th Sep 20255:12 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.